logo
China's lunar lander aces touchdown and takeoff tests ahead of planned 2030 crewed moon mission (video)

China's lunar lander aces touchdown and takeoff tests ahead of planned 2030 crewed moon mission (video)

Yahoo4 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
China's plan to launch astronauts to the moon has taken a major step forward.
The country subjected its "Lanyue" two-person lunar lander to a comprehensive landing and takeoff verification test this week at a unique facility in Huailai County, in northern China's Hebei Province.
Lanyue, whose name means "embracing the moon," is a crew-carrying lunar descent and ascent vehicle that's being developed for China's first human lunar exploration mission, which is slated to occur before 2030.
Key step
The test, completed on Aug. 6, represents a key step in the development of China's human lunar exploration program. It marked the first time that China has carried out a trial for the off-Earth landing and takeoff of a crew-carrying spacecraft, according to the China Manned Space Agency (CMSA).
Such testing appraises the performance of the moon lander under different scenarios throughout the landing and takeoff processes.
"For instance, during the launch phase, we need to verify its launch payload. So we conducted large-scale mechanical tests to ensure a smooth transition in the extremely complex environment during the launch," Huang Zhen, from the China Aerospace Science and Technology Corporation (CASC), told the state-run broadcaster China Central Television (CCTV).
CASC is responsible for the development and launch of the rockets and spacecraft for the China Lunar Exploration Program (CLEP). At present, CASC is also advancing follow-on tasks for CLEP.
Top priority: safety
Lanyue can carry two crew members to the moon's surface and is also equipped to transport a lunar rover and scientific payloads. Safety of astronauts is always the top priority, said Huang.
"For example, the lander has multiple engines that are arranged in a redundant configuration to back up each other. In the event of a failure of any single engine, [the remaining engines] can safely bring the astronauts back to the lunar orbit, enabling them to return home on Earth," Huang told CCTV.
According to CCTV, during the test, Lanyue's engines were ignited, mimicking the probe's landing on the moon and subsequent takeoff.
"The test validated the lander's landing and takeoff system, control plan, lunar contact shutdown procedures, and the compatibility of interfaces between subsystems, including guidance, navigation control (GNC) and propulsion," CCTV reported.
RELATED STORIES
— How China plans to put astronauts on the moon by 2030 (video)
— China names the spacecraft that will put its astronauts on the moon (video)
— 'We want to get there first and claim that for America': NASA chief explains push for nuclear reactor on the moon (video)
Minimize weight
"For our manned space missions, we must ensure that astronauts land on the lunar surface very comfortably and smoothly, which necessitates high standards for the lander's cushioning and landing performance. The lander is equipped with four landing legs, all designed to provide excellent cushioning during landing," Huang told CCTV.
"The lander undertakes a multitude of tasks, presenting significant design challenges. Every bit of weight has to play a role in several functions, so we have to achieve [the] ultimate in integrated design and lightweight construction," Huang added. "We have employed every possible method to minimize weight, achieving the most complex and sophisticated design purpose with the least launch weight."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Low FT3 Levels Predict Risk for Nerve Damage in Diabetes
Low FT3 Levels Predict Risk for Nerve Damage in Diabetes

Medscape

time15 hours ago

  • Medscape

Low FT3 Levels Predict Risk for Nerve Damage in Diabetes

TOPLINE: In euthyroid patients with type 2 diabetes (T2D), relatively higher free triiodothyronine (FT3) levels within the normal range were linked to a lower risk for diabetic peripheral neuropathy and better nerve function. METHODOLOGY: In euthyroid patients with T2D, lower FT3 levels within the normal range can worsen glucose and lipid metabolism and increase the risk for nephropathy and retinopathy, but the association of FT3 levels with peripheral neuropathy remains unclear. Researchers in China examined the relationship between FT3 levels and diabetic peripheral neuropathy in 1422 euthyroid patients with T2D (mean age, 58.04 years; 33.97% women) who underwent electromyography during hospitalization. Participants were considered euthyroid if their thyroid-stimulating hormone level was 0.25-5.5 IU/mL, free thyroxine level was 9.0-25.5 pmol/L, and FT3 level was 2.5-7.0 pmol/L. A diagnosis of diabetic peripheral neuropathy was made in those who showed neuropathic symptoms (neuropathic pain, paresthesias, numbness, sensory distortion, unsteadiness, or falls) and signs (pain sensation abnormalities, vibration sensation abnormalities, loss of the ankle reflex, touch/pressure sensation abnormalities, or temperature sensation abnormalities) during or after confirmed diabetes diagnosis. Nerve conduction studies of the distal limbs (median, ulnar, common peroneal, sural, and superficial peroneal nerves) were conducted in all participants, and distal motor and sensory nerve latencies, action potential amplitudes, and conduction velocities of motor and sensory nerves were recorded. TAKEAWAY: Among all participants with T2D, the 519 who were diagnosed with diabetic peripheral neuropathy showed significantly lower serum FT3 levels than those without the condition (P < .001). The risk for diabetic peripheral neuropathy was reduced in participants with FT3 levels between 4.3 and 4.7 pmol/L (odds ratio [OR], 0.57; 95% CI, 0.39-0.81) and 4.7 and 7.0 pmol/L (OR, 0.33; 95% CI, 0.21-0.52) compared with those with FT3 levels between 2.5 and 3.8 pmol/L. Participants with neuropathy had slower, weaker nerve responses and longer latencies than those without, with higher FT3 levels in patients with diabetic peripheral neuropathy being linked to faster nerve conduction and shorter latencies. A Mendelian randomization analysis using the ThyroidOmics Consortium and the UK Biobank genome-wide association study data also indicated a causal relationship between low FT3 levels and the risk for diabetic peripheral neuropathy (inverse variance weighted β = -0.655; P = .035). IN PRACTICE: 'Within the normal range, a relatively high level of FT3 (> 4.3 pmol/L) was associated with a reduced risk of DPN [diabetic peripheral neuropathy]. Thyroid hormones may be beneficial for patients with DPN if their FT3 levels are near the low end of the normal range,' the authors of the study wrote. SOURCE: This study was led by Bing'er Xu, Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China. It was published online in the Journal of Clinical Endocrinology and Metabolism. LIMITATIONS: This study was limited by its single-center design and focused on hospitalized patients with T2D in Shanghai. It measured only specific peripheral nerves' conduction parameters. The Mendelian randomization analysis was conducted only in Europeans, requiring validation in other ethnic populations. DISCLOSURES: This study received support from the National Science and Technology Major Project, the National Natural Science Foundation of China, the Science and Technology Commission of Shanghai Municipality, and other sources. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033
Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033

Yahoo

time15 hours ago

  • Yahoo

Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033

The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 billion by 2033 with a CAGR of 12.99%. Key technologies like digital PCR, liquid biopsy, and next-generation sequencing are driving growth amid rising cancer rates in China, India, and Japan. While high costs and a shortage of skilled professionals challenge expansion, collaborations and innovations are enhancing molecular diagnostic adoption. Strategic efforts, including AI, reimbursement standardization, and genomic literacy programs, aim to advance precision oncology in the APAC region, addressing barriers and harnessing growth opportunities. Asia-Pacific Molecular Oncology Diagnostics Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033" has been added to Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1.54 billion by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan. The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $513.6 Million Forecasted Market Value (USD) by 2033 $1542 Million Compound Annual Growth Rate 12.9% Regions Covered Asia Pacific APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges: Market Trends Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring. Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms. Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia. Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput. Market Drivers Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics. Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways. Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines. Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity. Market Challenges High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets. Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches. Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout. Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns. Market Segmentation: Cancer Type Solid Tumors Hematologic Malignancies End User Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Region Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Scientists find possible artefacts of oldest known Wallacean hominids in Indonesia
Scientists find possible artefacts of oldest known Wallacean hominids in Indonesia

Yahoo

time21 hours ago

  • Yahoo

Scientists find possible artefacts of oldest known Wallacean hominids in Indonesia

SOPPENG, Indonesia (Reuters) -Scientists have found a series of stone tools on Indonesia's Sulawesi island they say may be evidence of humans living 1.5 million years ago on islands between Asia and Australia, the earliest known humans in the Wallacea region. Archaeologists from Australia and Indonesia found the small, chipped tools, used to cut little animals and carve rocks, under the soil in the region of Soppeng in South Sulawesi. Radioactive tracing of these tools and the teeth of animals found around the site were dated at up to 1.48 million years ago. The findings could transform theories of early human migrations, according to an article the archaeologists published in the journal Nature in August. The earliest Wallacean humans, pre-historic persons known as Homo Erectus, were thought to have only settled in Indonesia's Flores island and Philippines' Luzon island around 1.02 million years ago, as they were thought to be incapable of distant sea travel, proving the significance of the Sulawesi findings in theories of migration. 'These were artefacts made by ancient humans who lived on the earth long before the evolution of our species, Homo Sapiens,' said Adam Brumm, lead archaeologist from Griffith University in Queensland, Australia. 'We think Homo Erectus somehow got from the Asian mainland across a significant ocean gap to this island, Sulawesi, at least 1 million years ago," Brumm said. Wallacea is a region in Eastern Indonesia including several islands such as Sulawesi, Lombok, Flores, Timor, Sumbawa that lie between Borneo and Java and Australia and New Guinea. The region is named for the naturalist Alfred Russel Wallace who studied the fauna and flora of the area. Solve the daily Crossword

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store